The new staff would grow WMP to 10 advisers and 28 staff available to service client needs.
P&N Group general manager strategy and corporate development, Kim Radalj, said that the search for a purchaser focused on finding a dedicated financial planning business that would share a similar values set and track record of building long-term client relationships to ensure the best possible outcome for PNFP’s financial planning clients.
“For nearly 20 years, WMP has prided itself on providing quality advice and a high standard of service to our clients,” WMP managing partner, Steve Beattie, said.
“We’ve built a strong reputation which has seen us grow to become one of Western Australia’s largest self-licensed financial planning businesses, with a focus on retirement advice and a client base of more than 1,100 families.
Notice to the Extraordinary General Meeting of Citycon Oyj finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
LaingBuisson News
Sander Slootweg, managing partner and co-founder of Forbion
European life sciences venture capital firm, Forbion, has announced the final close of its Forbion Growth 1 Fund at â¬360m (US$428m). The fund is focused on investing in late-stage life sciences companies, particularly European companies that develop novel therapies for areas of high medical need. The hard cap exceeds the original target size of â¬250m.
Forbion uses three strategies that aim to provide: private growth capital for clinical stage development assets, cross-over capital to companies aiming to pursue a public listing in the near-term, as well as capital injections that support existing under-valued public companies. It plans to take a leading position in its targets with an investment size of up to â¬35m per deal.
(0)
Fund launched in July 2020 invests in late-stage European life science companies
Fund now closed at the hard cap, with investors that include Pantheon, Eli Lilly and Company, Horizon Therapeutics plc (Nasdaq: HZNP), the Belgian Growth Fund, New Waves Investments, Wealth Management Partners, KfW Capital and the European Investment Fund (EIF)
First three investments made from fund
Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I ( Forbion Growth I ) at the hard cap amount of EUR 360 million (USD 428 million). Forbion Growth I is focused on investing in late-stage European life sciences companies.
Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million) financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.